Novo Holdings, the principal shareholder of Denmark’s Novo Nordisk (CPH: NOVO-B), has announced a definitive agreement to acquire contract development and manufacturing organization (CDMO) Catalent (NYSE: CTLT) for $16.5 billion. The transaction is expected to be finalized by the end of the year, pending customary regulatory conditions.
This acquisition comes in the wake of Catalent’s initiative last year to optimize its value through a comprehensive review of its business strategy, operations, and capital allocation priorities.
Following the completion of the transaction, Novo Holdings plans to divest three sterile fill-finish facilities from Catalent, located in Belgium, Italy, and the United States, to Novo Nordisk. This $11 billion deal will enhance Novo Nordisk’s filling capacity starting in 2026 and aligns with the company’s strategy to address the growing global demand for diabetes and obesity treatments.
Novo Nordisk has committed to fulfilling all customer obligations associated with the facilities.- Flcube.com
